CROSSCHECK-101: Accelerating Phase 1 Development for a Novel T-cell Engager in Relapsed or Refractory Hematologic Malignancies
Time: 11:30 am
day: Day 1
Details:
- Leveraging forward-thinking dose-finding strategies, including quantitative-systemspharmacology modeling to inform the starting dose
- Designing an innovative trial to expedite escalation while balancing optimal characterization of a recommended phase 2 dose and mitigation strategies for cytokine release syndrome
- Developing early clinical development strategies to maximize meaningful collection of safety and preliminary efficacy in a phase 1 setting